According to Gram Research analysis, two genes called RCC1 and PHACTR4 appear to influence how well men survive prostate cancer after diagnosis. A 2026 research study found that elevated RCC1 expression was linked to faster cancer recurrence, while higher PHACTR4 expression appeared in more aggressive tumors with higher Gleason grades. These genetic markers could eventually help doctors predict which patients need more intensive treatment, though the findings require validation in other populations before clinical use.
Scientists discovered that two genes called RCC1 and PHACTR4 may play important roles in how well men survive prostate cancer after diagnosis. Using advanced genetic analysis, researchers studied data from thousands of men and found that these genes could help doctors predict which patients might have more aggressive cancers or faster disease progression. This discovery could eventually help doctors personalize treatment plans and give patients better information about their outlook. However, the research was only done in people of European ancestry, so scientists need to study other populations to confirm these findings.
Key Statistics
A 2026 transcriptome-wide association study published in the European Journal of Human Genetics identified seven genes on chromosome 1 associated with prostate cancer survival, with RCC1 and PHACTR4 emerging as the most significant markers.
Research showed that elevated RCC1 expression was linked to shorter time to biochemical recurrence in prostate cancer patients, suggesting this gene may serve as a marker for more aggressive disease.
The study found that higher PHACTR4 expression was observed in prostate tumors with higher Gleason grades, a standard measure of cancer aggressiveness, indicating this gene may predict tumor behavior.
The Quick Take
- What they studied: Whether specific genes affect how long men survive after being diagnosed with prostate cancer
- Who participated: Men from two large cancer studies: the Malmö Diet and Cancer study (discovery group) and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (validation group). Participants were primarily of European ancestry.
- Key finding: Seven genes on chromosome 1 were linked to prostate cancer survival, with RCC1 and PHACTR4 being the most important. High RCC1 levels meant cancer came back faster, while high PHACTR4 levels appeared in more aggressive tumors.
- What it means for you: These genetic markers might one day help doctors predict which prostate cancer patients need more aggressive treatment. However, this research is still early-stage and needs confirmation in other populations before it changes medical practice.
The Research Details
Researchers used a technique called transcriptome-wide association studies (TWAS), which is a fancy way of saying they looked at which genes are turned on or off in cancer cells and matched that information with patient outcomes. They created computer models that could predict gene activity using normal prostate tissue, tumor tissue, and metastatic (spread) tumor tissue. Then they tested these models in two independent groups of patients to see if the same genes predicted survival in both groups.
The study used data from two major cancer research projects: the Malmö Diet and Cancer study provided the initial discovery data, and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial provided independent validation. This two-step approach (finding something in one group, then confirming it in another) is considered more reliable than studying just one group.
The researchers focused specifically on genes in the prostate tissue because that’s where prostate cancer starts, making the findings more relevant than studying genes from other body parts.
This research approach is important because it bridges the gap between basic genetics and real patient outcomes. Instead of just finding genes that differ between cancer and normal tissue, the researchers specifically looked for genes that predicted survival—the outcome that matters most to patients. By using multiple tissue types (normal, primary tumor, and metastatic tumor), they could see which genes were important at different stages of disease.
The study’s strength comes from using two independent patient groups to validate findings, which reduces the chance of false discoveries. However, the research has important limitations: it only included people of European ancestry, so results may not apply to other populations; it shows associations (correlations) rather than proving cause-and-effect; and the specific sample sizes for each analysis weren’t provided in the abstract. The findings are preliminary and require laboratory experiments to understand how these genes actually affect cancer behavior.
What the Results Show
The researchers identified seven genes on chromosome 1 that were associated with prostate cancer survival. Two genes came from analysis of normal prostate tissue models, while five came from analysis of metastatic tumor tissue models. This suggests that different genes become important at different stages of cancer development.
The two most important genes were RCC1 and PHACTR4. When RCC1 expression was elevated (meaning the gene was very active), patients experienced biochemical recurrence—a sign that cancer was coming back—more quickly. This suggests that high RCC1 activity might be a warning sign of more aggressive disease. PHACTR4 showed a different pattern: higher expression was found in tumors with higher Gleason grades, which is a standard measure of cancer aggressiveness. Higher Gleason grades mean the cancer cells look more abnormal under the microscope and tend to grow faster.
The fact that these genes were identified in both the discovery group and validation group strengthens confidence in the findings, though the validation group results weren’t detailed in the abstract.
The study found that using prediction models from different tissue types (normal versus metastatic tumor tissue) identified different genes. This suggests that the genes controlling cancer survival may change as cancer progresses from early to advanced stages. The identification of seven genes at a single location on chromosome 1 suggests this region of the genome may be particularly important for prostate cancer outcomes.
While prostate cancer is known to be highly heritable (meaning genetics play a big role), relatively few genes have been specifically linked to survival after diagnosis. This study adds to a growing body of research using transcriptome-wide association studies to identify genes affecting disease outcomes. The focus on tissue-specific gene expression (looking at genes in prostate tissue specifically) represents an advancement over earlier studies that didn’t account for which tissue type was being studied.
The study was limited to people of European ancestry, so the findings may not apply to men of African, Asian, Hispanic, or other ancestries—populations that sometimes have different genetic patterns and different prostate cancer outcomes. The research shows associations (correlations) between gene activity and survival, but doesn’t prove that these genes actually cause the survival differences; laboratory experiments would be needed to establish causality. The abstract doesn’t provide specific sample sizes for each analysis, making it difficult to assess statistical power. Finally, this is a genetic association study, not a clinical trial, so it cannot yet guide treatment decisions.
The Bottom Line
These findings are currently for research purposes only and should not change medical practice yet. Men with prostate cancer should continue following their doctor’s recommended treatment and monitoring plans. In the future, genetic testing for RCC1 and PHACTR4 expression might help personalize treatment decisions, but this would require validation in clinical trials and confirmation in diverse populations. Confidence level: Low to Moderate (early-stage research requiring further validation).
Men with prostate cancer or family history of prostate cancer may find this research interesting as it could eventually improve personalized medicine. Researchers studying prostate cancer genetics should pay attention to these findings. Men of non-European ancestry should note that these findings haven’t been validated in their populations yet. Healthcare providers may want to monitor this research as it develops toward clinical applications.
This is basic research, not a treatment. There’s no timeline for seeing personal health benefits. It typically takes 5-10 years for genetic discoveries to translate into clinical tests or treatment changes. Validation studies in other populations would need to happen first, followed by clinical trials to test whether knowing these gene levels actually improves treatment outcomes.
Frequently Asked Questions
What are RCC1 and PHACTR4 genes and why do they matter for prostate cancer?
RCC1 and PHACTR4 are genes that appear to influence how aggressive prostate cancer becomes and how quickly it returns after treatment. A 2026 study found that high RCC1 activity predicted faster cancer recurrence, while high PHACTR4 activity appeared in more aggressive tumors, potentially helping doctors predict patient outcomes.
Can genetic testing for these genes help predict my prostate cancer survival?
Not yet. This research is still preliminary and only studied people of European ancestry. Before genetic testing becomes available, scientists need to validate these findings in other populations and conduct clinical trials proving the tests actually improve treatment decisions and outcomes.
How did researchers discover these genes were important for prostate cancer survival?
Scientists used advanced genetic analysis called transcriptome-wide association studies to examine which genes were active in prostate cancer tissue and matched that information with patient survival data from two large cancer studies. They found seven genes on chromosome 1 linked to survival, with RCC1 and PHACTR4 being most significant.
Does this research mean I should change my prostate cancer treatment?
No. This is early-stage research showing associations, not proven cause-and-effect relationships. Continue following your doctor’s treatment recommendations. In the future, genetic testing might personalize treatment, but that requires additional research and clinical validation first.
Will these genetic findings apply to men of all races and ethnicities?
The study only included people of European ancestry, so results may not apply to other populations. Scientists need to validate these findings in African, Asian, Hispanic, and other ancestry groups before confirming whether RCC1 and PHACTR4 affect survival similarly across all populations.
Want to Apply This Research?
- Users with prostate cancer could track PSA levels (a blood test marker) and Gleason grade from their pathology reports over time, noting any changes that might correlate with genetic risk factors their doctor identifies.
- Set reminders for regular prostate cancer screening appointments and doctor follow-ups. Users could also document family history of prostate cancer in their health profile, as this research highlights the genetic basis of prostate cancer outcomes.
- Long-term tracking of PSA test results, imaging findings, and clinical assessments. Users should maintain detailed records of their cancer stage, grade, and any treatments received to share with healthcare providers who may eventually order genetic testing based on this emerging research.
This research is preliminary and for informational purposes only. The findings show genetic associations in people of European ancestry and have not been validated in other populations. These genes have not been proven to cause prostate cancer survival differences, only to be associated with them. Genetic testing for RCC1 and PHACTR4 is not currently available for clinical use. Men with prostate cancer should continue following their oncologist’s treatment recommendations and should not make medical decisions based on this research alone. Anyone with concerns about prostate cancer risk or survival should consult with their healthcare provider or a genetic counselor.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.